Biotech Values

[DewDiligence]

MNTA TEVA – Highly unlikely, IMO, that anything of consequence to investors is happening with the Copaxone patent litigation, which figures to be a drawn-out affair. Moreover, one could plausibly argue that the FDA rather than the patent litigation is the gating factor on generic Copaxone.